Pharmacologic administration of FGF21 imparts resistance to high-fat-diet–induced weight gain, improves glucose tolerance and hepatic and peripheral insulin sensitivity (without triggering hypoglycemia), and normalizes hyperinsulinemia and hypertriglyceridemia. The gene discussed is INS; the disease is hyperinsulinism.